{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-VEGF+Therapy&page=3", "query": { "intervention": "Anti-VEGF Therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 403, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-VEGF+Therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-VEGF+Therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T03:17:15.385Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05542381", "title": "The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Loteprednol Etabonate Ophthalmic Gel [Lotemax]", "type": "DRUG" }, { "name": "Refresh Lubricant Eye Drops [Artificial Tears]", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Virginia Polytechnic Institute and State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2022-12-22", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 1, "location_summary": "Roanoke, Virginia", "locations": [ { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05542381" }, { "nct_id": "NCT00094107", "title": "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Skin Neoplasms" ], "interventions": [ { "name": "Axitinib [AG-013736]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2004-12", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2012-06-26", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 11, "location_summary": "Orange, California • Miami Beach, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094107" }, { "nct_id": "NCT02873195", "title": "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Recurrent Colorectal Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-07-07", "completion_date": "2023-12-01", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873195" }, { "nct_id": "NCT06825858", "title": "A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "KH658", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chengdu Origen Biotechnology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 9, "start_date": "2025-04-07", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Lemont, Illinois • Memphis, Tennessee", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lemont", "state": "Illinois" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06825858" }, { "nct_id": "NCT05984927", "title": "NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "NG101 AAV gene therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Elisigen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 20, "start_date": "2023-09-08", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984927" }, { "nct_id": "NCT00255762", "title": "Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2005-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-28", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00255762" }, { "nct_id": "NCT01383343", "title": "Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2011-08", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383343" }, { "nct_id": "NCT04592419", "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Retinal Vein Occlusion" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 568, "start_date": "2020-09-25", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 81, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592419" }, { "nct_id": "NCT07271355", "title": "Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Appendix Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Malignant Neoplasm in the Peritoneum", "Stage IV Appendix Carcinoma AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Unresectable Colorectal Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2026-10-01", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 5, "location_summary": "Goodyear, Arizona • Duarte, California • Irvine, California + 2 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07271355" }, { "nct_id": "NCT00492284", "title": "Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Choroidal Neovascularization", "Macular Degeneration" ], "interventions": [ { "name": "verteporfin", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QLT Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 162, "start_date": "2007-07", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2011-06-02", "last_synced_at": "2026-10-09T03:17:15.385Z", "location_count": 21, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492284" } ] }